Cargando…
Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021
To assess the real-world impact of vaccines on COVID-19 related outcomes, we analysed data from over 7 million recipients of at least one COVID-19 vaccine dose in Italy. Taking 0–14 days post-first dose as reference, the SARS-CoV-2 infection risk subsequently decreased, reaching a reduction by 78% (...
| Autores principales: | , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Centre for Disease Prevention and Control (ECDC)
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229378/ https://www.ncbi.nlm.nih.gov/pubmed/34169819 http://dx.doi.org/10.2807/1560-7917.ES.2021.26.25.2100507 |
| _version_ | 1783712963239084032 |
|---|---|
| author | Mateo-Urdiales, Alberto Spila Alegiani, Stefania Fabiani, Massimo Pezzotti, Patrizio Filia, Antonietta Massari, Marco Riccardo, Flavia Tallon, Marco Proietti, Valeria Del Manso, Martina Puopolo, Maria Spuri, Matteo Morciano, Cristina D’Ancona, Fortunato (Paolo) Da Cas, Roberto Battilomo, Serena Bella, Antonino Menniti-Ippolito, Francesca |
| author_facet | Mateo-Urdiales, Alberto Spila Alegiani, Stefania Fabiani, Massimo Pezzotti, Patrizio Filia, Antonietta Massari, Marco Riccardo, Flavia Tallon, Marco Proietti, Valeria Del Manso, Martina Puopolo, Maria Spuri, Matteo Morciano, Cristina D’Ancona, Fortunato (Paolo) Da Cas, Roberto Battilomo, Serena Bella, Antonino Menniti-Ippolito, Francesca |
| author_sort | Mateo-Urdiales, Alberto |
| collection | PubMed |
| description | To assess the real-world impact of vaccines on COVID-19 related outcomes, we analysed data from over 7 million recipients of at least one COVID-19 vaccine dose in Italy. Taking 0–14 days post-first dose as reference, the SARS-CoV-2 infection risk subsequently decreased, reaching a reduction by 78% (incidence rate ratios (IRR): 0.22; 95% CI: 0.21–0.24) 43–49 days post-first dose. Similarly, hospitalisation and death risks decreased, with 89% (IRR: 0.11; 95% CI: 0.09–0.15) and 93% (IRR: 0.07; 95% CI: 0.04–0.11) reductions 36–42 days post-first dose. Our results support ongoing vaccination campaigns. |
| format | Online Article Text |
| id | pubmed-8229378 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Centre for Disease Prevention and Control (ECDC) |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-82293782021-07-02 Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021 Mateo-Urdiales, Alberto Spila Alegiani, Stefania Fabiani, Massimo Pezzotti, Patrizio Filia, Antonietta Massari, Marco Riccardo, Flavia Tallon, Marco Proietti, Valeria Del Manso, Martina Puopolo, Maria Spuri, Matteo Morciano, Cristina D’Ancona, Fortunato (Paolo) Da Cas, Roberto Battilomo, Serena Bella, Antonino Menniti-Ippolito, Francesca Euro Surveill Rapid Communication To assess the real-world impact of vaccines on COVID-19 related outcomes, we analysed data from over 7 million recipients of at least one COVID-19 vaccine dose in Italy. Taking 0–14 days post-first dose as reference, the SARS-CoV-2 infection risk subsequently decreased, reaching a reduction by 78% (incidence rate ratios (IRR): 0.22; 95% CI: 0.21–0.24) 43–49 days post-first dose. Similarly, hospitalisation and death risks decreased, with 89% (IRR: 0.11; 95% CI: 0.09–0.15) and 93% (IRR: 0.07; 95% CI: 0.04–0.11) reductions 36–42 days post-first dose. Our results support ongoing vaccination campaigns. European Centre for Disease Prevention and Control (ECDC) 2021-06-24 /pmc/articles/PMC8229378/ /pubmed/34169819 http://dx.doi.org/10.2807/1560-7917.ES.2021.26.25.2100507 Text en This article is copyright of the authors or their affiliated institutions, 2021. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made. |
| spellingShingle | Rapid Communication Mateo-Urdiales, Alberto Spila Alegiani, Stefania Fabiani, Massimo Pezzotti, Patrizio Filia, Antonietta Massari, Marco Riccardo, Flavia Tallon, Marco Proietti, Valeria Del Manso, Martina Puopolo, Maria Spuri, Matteo Morciano, Cristina D’Ancona, Fortunato (Paolo) Da Cas, Roberto Battilomo, Serena Bella, Antonino Menniti-Ippolito, Francesca Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021 |
| title | Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021 |
| title_full | Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021 |
| title_fullStr | Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021 |
| title_full_unstemmed | Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021 |
| title_short | Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021 |
| title_sort | risk of sars-cov-2 infection and subsequent hospital admission and death at different time intervals since first dose of covid-19 vaccine administration, italy, 27 december 2020 to mid-april 2021 |
| topic | Rapid Communication |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229378/ https://www.ncbi.nlm.nih.gov/pubmed/34169819 http://dx.doi.org/10.2807/1560-7917.ES.2021.26.25.2100507 |
| work_keys_str_mv | AT mateourdialesalberto riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 AT spilaalegianistefania riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 AT fabianimassimo riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 AT pezzottipatrizio riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 AT filiaantonietta riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 AT massarimarco riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 AT riccardoflavia riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 AT tallonmarco riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 AT proiettivaleria riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 AT delmansomartina riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 AT puopolomaria riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 AT spurimatteo riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 AT morcianocristina riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 AT danconafortunatopaolo riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 AT dacasroberto riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 AT battilomoserena riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 AT bellaantonino riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 AT mennitiippolitofrancesca riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 AT riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 AT riskofsarscov2infectionandsubsequenthospitaladmissionanddeathatdifferenttimeintervalssincefirstdoseofcovid19vaccineadministrationitaly27december2020tomidapril2021 |